Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Aimmune Therapeutics Inc    AIMT

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/13/2017 11/14/2017 11/15/2017 11/16/2017 11/17/2017 Date
34.64(c) 34.82(c) 34.91(c) 35.28(c) 34.95(c) Last
726 555 609 311 325 736 317 998 358 043 Volume
+2.58% +0.52% +0.26% +1.06% -0.94% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -128 M
Net income 2017 -125 M
Finance 2017 103 M
Yield 2017 -
Sales 2018 -
EBIT 2018 -178 M
Net income 2018 -176 M
Finance 2018 22,3 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 0
EV / Sales2018 0
Capitalization 1 778 M
More Financials
Company
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company.It engages in the research and development of desensitization treatments for peanut and other food allergies.The company's portfolio includes the characterized oral desensitization immunotherapy system.Its pipeline consists... 
Sector
Pharmaceuticals
Calendar
11/28 | 06:30pmPresentation
More about the company
Surperformance© ratings of Aimmune Therapeutics Inc
Trading Rating : Investor Rating : -
More Ratings
Latest news on AIMMUNE THERAPEUTICS INC
11/07 AIMMUNE THERAPEUTICS : Announces Third Quarter 2017 Financial Results and Planne..
11/06 AIMMUNE THERAPEUTICS : Management's Discussion and Analysis of Financial Conditi..
11/06 AIMMUNE THERAPEUTICS, INC. (NASDAQ : AIMT) Files An 8-K Results of Operations an..
11/06 AIMMUNE THERAPEUTICS, INC. : Results of Operations and Financial Condition, Chan..
11/06 AIMMUNE THERAPEUTICS : reports 3Q loss
11/06 AIMMUNE THERAPEUTICS : Announces Third Quarter 2017 Financial Results and Planne..
11/01 AIMMUNE THERAPEUTICS : to Participate in Four Investor Conferences in November
10/31 AIMMUNE THERAPEUTICS ANNOUNCES PUBLI : In Practice of Positive AR101 Data from A..
10/26 AIMMUNE THERAPEUTICS : Announces Clinical Collaboration to Study AR101 with Rege..
10/19 AIMMUNE THERAPEUTICS : to Present Data on Peanut Allergy at ACAAI and PAAM Medic..
More news
Sector news : Specialty & Advanced Pharmaceuticals
11/18DJADRs End Higher; JA Solar, NetEase Trade Actively
11/17 British stocks fall back as Carillion crashes, Sky soars
11/17DJROCHE : U.S. FDA Approves Roche's Gazyva for Untreated Follicular Lymphoma
11/17DJROCHE : to Acquire U.S. Software Company Viewics
11/16 Europe approves GlaxoSmithKline's new triple lung drug
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
11/17 Aimmune Therapeutics (AIMT) Presents At Jefferies 2017 London Healthcare Conf..
11/12 Market Wisdom From A Bioscience Expert - An Integrated BioSci Interview
11/06 Aimmune Therapeutics beats by $0.09
10/26 DAILY INSIDER RATINGS ROUND UP 10/25 : Taco, appn, bcbp, pch, sxcp
10/26 YOUR DAILY PHARMA SCOOP : Roche's Investment Potential, Sarepta Lifts Guidance, ..
Chart AIMMUNE THERAPEUTICS INC
Duration : Period :
Aimmune Therapeutics Inc Technical Analysis Chart | AIMT | US00900T1079 | 4-Traders
Technical analysis trends AIMMUNE THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 47,8 $
Spread / Average Target 37%
EPS Revisions
Managers
NameTitle
Stephen George Dilly President, Chief Executive Officer & Director
Mark D. McDade Chairman
Jeffrey H. Knapp Chief Operating Officer
Eric H. Bjerkholt Chief Financial Officer
Daniel C. Adelman Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
AIMMUNE THERAPEUTICS INC70.90%1 778
ABBVIE49.49%149 223
MERCK KGAA-8.66%13 796
KYOWA HAKKO KIRIN CO LTD33.75%11 130
JAZZ PHARMACEUTICALS PLC22.78%8 026
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD42.96%6 074